8-K filing — BioCardia, Inc. (BCDA)
Filed: 2026-08-24 AccNo: 0001437749-26-028778 Size: 178 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
BioCardia Says FDA Finalized Pre-Submission Meeting Minutes For Helix Transendocardial Delivery Catheter; Plans Follow-On Pre-Submission This Quarter Toward Potential De Novo Approval
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioCardia Q2 EPS $(0.13) Beats $(0.18) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 67.5 percent increase over losses of $(0.40) per share from the
BioCardia CEO Issued Shareholder Letter To Provide Update; Milestone Includes Submission For Japan's Pharmaceutical and Medical Device Agency Approval Planned For End Of 2026; Driving To Enroll Confirmatory CardiAMP HF II Trial In US